Literature DB >> 11743622

Effect of pilocarpine mouthwash on salivary flow.

R Bernardi1, C Perin, F L Becker, G Z Ramos, G Z Gheno, L R Lopes, M Pires, H M T Barros.   

Abstract

Pilocarpine is a cholinergic agonist that increases salivary flow and has been used to treat xerostomia. Oral intake is the most frequent route of administration. Adverse effects are dose-dependent and include sudoresis, facial blushing and increased urinary frequency. The objective of the present study was to evaluate the effects of topical pilocarpine solutions as mouthwashes on salivary flow and their adverse effects on healthy subjects. Forty volunteers received 10 ml 0.5, 1 and 2% pilocarpine solutions or 0.9% saline in a randomized, double-blind, placebo-controlled manner. Salivation was measured before and 45, 60 and 75 min after mouth rinsing for 1 min with 10 ml of saline or pilocarpine solutions. Vital signs were measured and ocular, gastrointestinal and cardiovascular symptoms, anxiety and flushing were estimated using visual analog scales. There was a dose-dependent increase in salivation. Salivation measured after 1 and 2% pilocarpine (1.4 +/- 0.36 and 2.22 +/- 0.42 g, respectively) was significantly (P<0.001) higher than before (0.70 +/- 0.15 and 0.64 +/- 0.1 g), with a plateau between 45 and 75 min. Cardiovascular, visual, gastrointestinal and behavioral symptoms and signs were not changed by topical pilocarpine. Mouth rinsing with pilocarpine solutions at concentrations of 1 to 2% induced a significant objective and subjective dose-dependent increase in salivary flow, similar to the results reported by others studying the effect of oral 5 mg pilocarpine. The present study revealed the efficacy of pilocarpine mouthwash solutions in increasing salivary flow in healthy volunteers, with no adverse effects. Additional studies on patients with xerostomia are needed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11743622     DOI: 10.1590/s0100-879x2002000100015

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  10 in total

Review 1.  A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact.

Authors:  S B Jensen; A M L Pedersen; A Vissink; E Andersen; C G Brown; A N Davies; J Dutilh; J S Fulton; L Jankovic; N N F Lopes; A L S Mello; L V Muniz; C A Murdoch-Kinch; R G Nair; J J Napeñas; A Nogueira-Rodrigues; D Saunders; B Stirling; I von Bültzingslöwen; D S Weikel; L S Elting; F K L Spijkervet; M T Brennan
Journal:  Support Care Cancer       Date:  2010-03-25       Impact factor: 3.603

2.  Building a Functional Salivary Gland for Cell-Based Therapy: More than Secretory Epithelial Acini.

Authors:  Caitlynn M L Barrows; Danielle Wu; Mary C Farach-Carson; Simon Young
Journal:  Tissue Eng Part A       Date:  2020-09-21       Impact factor: 3.845

3.  Efficacy and safety of two artificial saliva-based polymers containing 0.1% pilocarpine for treatment of xerostomia: A randomized clinical pilot trial.

Authors:  Wilairat Sarideechaigul; Aroonsri Priprem; Sucharat Limsitthichaikoon; Pensri Phothipakdee; Rajda Chaijit; Teekayu P Jorns; Nopphakhun Lungruammit; Krittiporn Chaiya
Journal:  J Clin Exp Dent       Date:  2021-10-01

Review 4.  A Review on the Role of Pilocarpine on the Management of Xerostomia and the Importance of the Topical Administration Systems Development.

Authors:  Afroditi Kapourani; Konstantinos N Kontogiannopoulos; Panagiotis Barmpalexis
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-18

Review 5.  Diagnosis and treatment of xerostomia (dry mouth).

Authors:  Joel J Napeñas; Michael T Brennan; Philip C Fox
Journal:  Odontology       Date:  2009-07-29       Impact factor: 2.634

6.  Do pilocarpine drops help dry mouth in palliative care patients: a protocol for an aggregated series of n-of-1 trials.

Authors:  Jane Nikles; Geoffrey K Mitchell; Janet Hardy; Meera Agar; Hugh Senior; Sue-Ann Carmont; Philip J Schluter; Phillip Good; Rohan Vora; David Currow
Journal:  BMC Palliat Care       Date:  2013-10-31       Impact factor: 3.234

7.  New low-dose liquid pilocarpine formulation for treating dry mouth in Sjögren's syndrome: clinical efficacy, symptom relief, and improvement in quality of life.

Authors:  Machiko Watanabe; Chisato Yamada; Yoshinori Komagata; Hirotoshi Kikuchi; Hiroyuki Hosono; Fumio Itagaki
Journal:  J Pharm Health Care Sci       Date:  2018-03-01

8.  Localized Delivery of Pilocarpine to Hypofunctional Salivary Glands through Electrospun Nanofiber Mats: An Ex Vivo and In Vivo Study.

Authors:  Sujatha Muthumariappan; Wei Cheng Ng; Christabella Adine; Kiaw Kiaw Ng; Pooya Davoodi; Chi-Hwa Wang; Joao N Ferreira
Journal:  Int J Mol Sci       Date:  2019-01-28       Impact factor: 5.923

Review 9.  A Review on Xerostomia and Its Various Management Strategies: The Role of Advanced Polymeric Materials in the Treatment Approaches.

Authors:  Afroditi Kapourani; Konstantinos N Kontogiannopoulos; Alexandra-Eleftheria Manioudaki; Athanasios K Poulopoulos; Lazaros Tsalikis; Andreana N Assimopoulou; Panagiotis Barmpalexis
Journal:  Polymers (Basel)       Date:  2022-02-22       Impact factor: 4.329

10.  Efficacy of Pilocarpine and Bromhexine in Improving Radiotherapy-induced Xerostomia.

Authors:  Farid Abbasi; Sareh Farhadi; Mostafa Esmaili
Journal:  J Dent Res Dent Clin Dent Prospects       Date:  2013-05-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.